AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development,” said ...

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong ...

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next ...

Iraq's drug localization efforts save $1B annually, with 34 factories at full capacity & 178 new applications, says PM's ...

VCG. To support the innovative development of drugs and medical devices, China's National Healthcare Security Administration ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

A constantly updated RAG architecture mitigates the risks of a stale AI system by ensuring AI outputs reflect the latest ...

Neurizon Therapeutics, Arovella Therapeutics and Singular Health Group are among ASX health companies reporting quarterly ...

In this symposium, an expert panel will discuss how the latest organoid models help researchers discover and develop new ...